4th March 2011
Amgen Completes Acquisition of BioVex
Amgen have announced the completion of the acquisition of BioVex Group, Inc., for up to $1 billion. The transaction provides Amgen with BioVex’s lead product candidate, OncoVEXGM-CSF, a novel oncolytic vaccine in Phase 3 clinical development.
Read this article
21st February 2011
Meda Acquires Antula
Meda has signed an agreement to acquire Antula with well-known brands such as SB12, Anti, Zyx, Becur, Ac3, Lactal Balans, Eeze, Nalox and Inside for SEK 1,800 million on a debt-free basis.
Read this article
24th January 2011
BioVex to be acquired by Amgen for up to $1bn
Amgen (Nasdaq: AMGN) and Biovex Group, Inc. announce that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, Inc. for up to $1 billion.
Read this article
1st November 2010
Vascular Pathways Completes Series B Financing
Vascular Pathways Inc., a privately held medical device company with a breakthrough product for peripheral intravenous access, has announced the closing of a $14 million Series B financing round
Read this article
22nd October 2010
Aegerion Pharmaceuticals Announces Pricing of Initial Public Offering
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), announces the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share
Read this article
News Archive
Last 5 Articles | Next 5 Articles
21st February 2011Meda Acquires Antula
Consistent step in Meda's OTC strategy
- Sales of about SEK 500 million with strong growth in the Nordic markets
- Well-established brands that will be launched internationally
- A strong pipeline of 3-4 new products that can be launched annually
Purchase price and time table
- Purchase consideration of SEK 1,800 million (on a debt-free basis)
- Financed using existing credit facilities
- The acquisition is expected to be completed within a couple of months
Meda has signed an agreement to acquire Antula with well-known brands such as SB12, Anti, Zyx, Becur, Ac3, Lactal Balans, Eeze, Nalox, and Inside. Antula is a growing company that concentrates on prescription-free (OTC) products. In five years, Antula has built strong brandnames and generated sales of some SEK 500 million just in the Nordics. Its integration with Meda opens doors to an international marketplace and broadens its potential through Meda's OTC organisation.
Meda has expressed its ambition to build a strong position in OTC products, an area that it has continually expanded in recent years. Antula’s and Meda's OTC products will together make up over 20% of Meda's total sales.
The acquisition of Antula offers Meda clear growth opportunities, partly through Meda and Antula's existing products, and partly through Antula's pipeline that consists of three to four new products annually. Antula is established in the Nordics with its own organization. Through the integration with Meda, several of the products will have potential to become internationally strong brands.
“We are pleased to welcome the Antula team to Meda. They have demonstrated their considerable expertise in consumer marketing and we are looking forward to an exciting future together," said Anders Lönner, CEO of Meda AB.
”I’m delighted that we have found a perfect home for Antula within Meda. This is the right step so we can unlock the value of Antula’s products on an international base with Meda’s organization. Antula’s pipeline also offers Meda an additional growth opportunity”, said Barry Clare, founder of Healthcare Brands International, Antula’s current owner.
The acquisition price for Antula is SEK 1,800 million on a debt-free basis. The acquisition will be financed using Meda's existing credit facilities. The transaction is subject to standard closing requirements and the approval of the competition authorities. The acquisition of Antula is expected to be completed within a couple of months.
| Associated Links Visit Meda AB |
Downloads Full Press Release |